Newly prescribed canagliflozin vs. GLP-1 agonists...

Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.

Abstract

SOURCE CITATION: Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. 32843476.

Authors

Hao Q; Guyatt G

Journal

Annals of Internal Medicine, Vol. 174, No. 1,

Publisher

American College of Physicians

Publication Date

January 1, 2021

DOI

10.7326/acpj202101190-011

ISSN

1056-8751

Associated Experts

Gordon Guyatt

Professor, Faculty of Health Sciences

Visit profile

Labels

Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team